The ACCESS Trial for Community-Acquired Pneumonia
I cannot identify any trial called "ACCESS" in the provided evidence related to community-acquired pneumonia. The evidence includes major guidelines from the American Thoracic Society/Infectious Diseases Society of America (2019,2001,2000), British Thoracic Society (2001), and various research studies, but none reference an ACCESS trial.
What the Evidence Does Contain
The provided guidelines and research discuss several important clinical trials and studies for CAP, but not ACCESS:
The Pneumonia Patient Outcome Research Team (Pneumonia PORT) developed the clinical prediction rule for short-term mortality and risk stratification into five severity classes 1
Falguera and colleagues (2007) conducted a randomized trial of 177 patients comparing pathogen-directed treatment based on urinary antigen testing versus empirical guideline-directed treatment, finding no statistical differences in death, clinical relapse, ICU admission, or length of hospitalization 1
ConsenSur I and II were South American working group guidelines for initial antimicrobial therapy based on local evidence, published in 2002 and updated in 2010 2, 3
Possible Explanations
The ACCESS trial may be:
- Referenced under a different name in the pneumonia literature
- A trial not included in the provided evidence base
- Related to a different aspect of pneumonia management not covered in these guidelines
- A trial from a different medical specialty or condition
If you can provide additional context about what aspect of pneumonia the ACCESS trial addressed (e.g., antibiotic selection, diagnostic approach, severity assessment), I can search for relevant information within the available evidence.